CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 398 enrolled
Drug / intervention
SoC + iTabdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01761643
NCT01761643Phase 4Completed
CompareCT.gov

CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM

University of California, San Diego·interventional·Posted Jan 7, 2013·Updated Jun 30, 2020

In Brief

A Phase 4 clinical trial evaluating SoC + iTab for Patient Adherence and HIV Seronegativity. Completed, enrolled 398 participants across 4 sites.

Detailed Summary

CCTG 595 is a controlled, open-label, two-arm, randomized (1:1) clinical demonstration project to determine if the use of a text-message based adherence intervention (iTAB) improves retention and adherence to PrEP compared to standard of care (SoC) PrEP delivery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatient Adherence, HIV Seronegativity
CountriesUnited States
CollaboratorsUniversity of California, Los Angeles, University of Southern California, City of Long Beach Department of Health and Human Services, California HIV/AIDS Research Program, Gilead Sciences

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 7, 2013
Enrollment StartDec 19, 2012
Primary CompletionJun 13, 2018
Study CompletionJul 11, 2018
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 13.5 years ago

Interventions

SoC + iTabdevice

Text messaging reminders to improve adherence to PrEP